TY - JOUR
T1 - Effects of pitavastatin versus atorvastatin on the peripheral endothelial progenitor cells and vascular endothelial growth factor in high-risk patients
T2 - A pilot prospective, double-blind, randomized study
AU - Lin, Liang Yu
AU - Huang, Chin Chou
AU - Chen, Jia Shiong
AU - Wu, Tao Cheng
AU - Leu, Hsin Bang
AU - Huang, Po Hsun
AU - Chang, Ting Ting
AU - Lin, Shing Jong
AU - Chen, Jaw Wen
N1 - Publisher Copyright:
© 2014 Lin et al.; licensee BioMed Central Ltd.
PY - 2014/7/16
Y1 - 2014/7/16
N2 - Background: Circulating endothelial progenitor cells (EPCs) reflect endothelial repair capacity and may be a significant marker for the clinical outcomes of cardiovascular disease. While some high-dose statin treatments may improve endothelial function, it is not known whether different statins may have similar effects on EPCs.This study aimed to investigate the potential class effects of different statin treatment including pitavastatin and atorvastatin on circulating EPCs in clinical setting. Methods: A pilot prospective, double-blind, randomized study was conducted to evaluate the ordinary dose of pitavastatin (2mg daily) or atorvastatin (10mg daily) treatment for 12weeks on circulating EPCs in patients with cardiovascular risk such as hypercholesterolemia and type 2 diabetes mellitus (T2DM). Additional in vitro study was conducted to clarify the direct effects of both statins on EPCs from the patients. Results: A total of 26 patients (19 with T2DM) completed the study. While the lipid-lowering effects were similar in both treatments, the counts of circulating CD34+KDR+EPCs were significantly increased (from 0.021 ± 0.015 to 0.054 ± 0.044% of gated mononuclear cells, P < 0.05) only by pitavastatin treatment. Besides, plasma asymmetric dimethylarginine level was reduced (from 0.68 ± 0.10 to 0.53 ± 0.12μmol/L, P < 0.05) by atorvastatin, and plasma vascular endothelial growth factor (VEGF) level was increased (from 74.33 ± 32.26 to 98.65 ± 46.64pg/mL, P < 0.05) by pitavastatin. In the in vitro study, while both statins increased endothelial nitric oxide synthase (eNOS) expression, only pitavastatin increased the phosphorylation of eNOS in EPCs. Pitavastatin but not atorvastatin ameliorated the adhesion ability of early EPCs and the migration and tube formation capacities of late EPCs. Conclusions: While both statins similarly reduced plasma lipids, only pitavastatin increased plasma VEGF level and circulating EPCs in high-risk patients, which is probably related to the differential pleiotropic effects of different statins. Trial registration: This trial is registered at ClinicalTrials.gov, NCT01386853.
AB - Background: Circulating endothelial progenitor cells (EPCs) reflect endothelial repair capacity and may be a significant marker for the clinical outcomes of cardiovascular disease. While some high-dose statin treatments may improve endothelial function, it is not known whether different statins may have similar effects on EPCs.This study aimed to investigate the potential class effects of different statin treatment including pitavastatin and atorvastatin on circulating EPCs in clinical setting. Methods: A pilot prospective, double-blind, randomized study was conducted to evaluate the ordinary dose of pitavastatin (2mg daily) or atorvastatin (10mg daily) treatment for 12weeks on circulating EPCs in patients with cardiovascular risk such as hypercholesterolemia and type 2 diabetes mellitus (T2DM). Additional in vitro study was conducted to clarify the direct effects of both statins on EPCs from the patients. Results: A total of 26 patients (19 with T2DM) completed the study. While the lipid-lowering effects were similar in both treatments, the counts of circulating CD34+KDR+EPCs were significantly increased (from 0.021 ± 0.015 to 0.054 ± 0.044% of gated mononuclear cells, P < 0.05) only by pitavastatin treatment. Besides, plasma asymmetric dimethylarginine level was reduced (from 0.68 ± 0.10 to 0.53 ± 0.12μmol/L, P < 0.05) by atorvastatin, and plasma vascular endothelial growth factor (VEGF) level was increased (from 74.33 ± 32.26 to 98.65 ± 46.64pg/mL, P < 0.05) by pitavastatin. In the in vitro study, while both statins increased endothelial nitric oxide synthase (eNOS) expression, only pitavastatin increased the phosphorylation of eNOS in EPCs. Pitavastatin but not atorvastatin ameliorated the adhesion ability of early EPCs and the migration and tube formation capacities of late EPCs. Conclusions: While both statins similarly reduced plasma lipids, only pitavastatin increased plasma VEGF level and circulating EPCs in high-risk patients, which is probably related to the differential pleiotropic effects of different statins. Trial registration: This trial is registered at ClinicalTrials.gov, NCT01386853.
KW - Atorvastatin
KW - Endothelial nitric oxide synthase
KW - Endothelial progenitor cell
KW - Hypercholesterolemia
KW - Pitavastatin
KW - Vascular endothelial growth factor
UR - http://www.scopus.com/inward/record.url?scp=84904518165&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904518165&partnerID=8YFLogxK
U2 - 10.1186/s12933-014-0111-1
DO - 10.1186/s12933-014-0111-1
M3 - Article
C2 - 25027585
AN - SCOPUS:84904518165
SN - 1475-2840
VL - 13
JO - Cardiovascular Diabetology
JF - Cardiovascular Diabetology
IS - 1
M1 - 111
ER -
